Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the VERITAC-2 (vepdegestrant) & SERENA-6 (camizestrant) ASCO data and impacts on the broader SERD landscape

Ticker(s): AVRN, AZN, LLY, PFE, OLMA

Who's the expert?

Institution: University of Cambridge

Clinical Senior Research Associate and Academic Consultant in Breast Cancer Therapeutics at the University of Cambridge.
Currently manages 30 patients with HR+/HER- breast cancer each month.
Focus on Early phase breast cancer clinical trials with expertise in first-in-human studies & drug combination trials, new small molecule & antibody therapeutics and the development of pharmacodynamic and predictive biomarkers.

Interview Goal

This conversation will focus on the recent ASCO 2025 data on SERDS:
SERENA-6 Trial (AstraZeneca – Camizestrant - Abstract Number: LBA4) & VERITAC-2 Trial (Arvinas/Pfizer – Vepdegestrant - Abstract Number: LBA1000). We will discuss the data and the impact on the broader SERD landscape.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Call Date: May 29, 2025
Call Time: 01:00 PM EDT

Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.